Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV

To evaluate safety and immunogenicity of V114 [15-valent pneumococcal conjugate vaccine (PCV) containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F], followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later, in adults living with HIV. DESIGN: I...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohapi, Lerato, Pinedo, Yvett, Osiyemi, Olayemi, Supparatpinyo, Khuanchai, Ratanasuwan, Winai, Molina, Jean-Michel, Dagan, Ron, Tamms, Gretchen, Sterling, Tina, Zhang, Ying, Pedley, Alison, Hartzel, Jon, Kan, Yanqing, Hurtado, Kim, Musey, Luwy, Simon, Jakub K., Buchwald, Ulrike K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815827/
https://www.ncbi.nlm.nih.gov/pubmed/34750291
http://dx.doi.org/10.1097/QAD.0000000000003126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815827/
https://www.ncbi.nlm.nih.gov/pubmed/34750291
http://dx.doi.org/10.1097/QAD.0000000000003126

Ejemplares similares